Press Release
DEA DIVERSION Scandal Exposed - Marijuana Drug Development Obstruction
DEA Back to Training School, DEA Bureaucrat Blocks Science While Ignoring their Own TRAINING Manual. DEA Assistant Administrators and attorney needs a summer assignment, and MMJ BioPharma Cultivation has a suggestion: go back and read your own policy statement and training manual. Read More
Press Release
Expansion of Tolmer 'Silver Zone' Drilling Program
Early surface reconnaissance and drilling progress sharpen silver focus HIGHLIGHTS Current ~2,500m reverse circulation (RC) drilling program underway at Tolmer discovery; planned gold drilling reallocated to prioritise silver zone following early observations1 Additional target holes added north, east, south and west of high-grade ‘discovery line'2 Read More
Press Release
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders. Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo. EXXUA is expected to serve as a major growth catalyst as Aytu continues to build value for shareholders; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts. Conference call to discuss the EXXUA opportunity and commercialization plan scheduled for Wednesday, June 11, 2025, at 4:30 p.m. Eastern time. Read More
Press Release
PRESS RELEASE: LIE to YOUR BANK and LOSE YOUR GUNS RIGHTS, Says US COURT of APPEALS. (Opinion Attached)
Zherka: ‘My Banks Got Paid, My Rights Got Taken' - Government Overreach Mirrors Trump's Political Witch Hunt Real estate titan vows Supreme Court appeal after court upholds lifetime gun ban for nonviolent conviction: “This is lawfare, plain and simple.” Read More
Press Release
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Click here to register Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trial The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company's core focus on orphan diseases Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer Read More
Press Release
Angel Ai Joins Forces With Global Leaders at Bitcoin 2025 to Shape the Future of Finance
Angel Ai CEO and fintech visionary Pavan Agarwal attended Bitcoin 2025, the largest Bitcoin event of the year, held in Las Vegas. The conference was a landmark moment in the evolving convergence of AI, blockchain, and digital currency, drawing high-profile speakers and innovators across industries-from government leaders like Vice president JD Vance, Eric Trump, Donald Trump Jr., NYC Mayor Eric Adams, and Bo Hines, the U.S. Head of Cryptocurrency, to real estate mogul Josh Altman, and high profile technology leaders like David Sacks, Michael Saylor, and Michael Terpin. Read More
Press Release
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer Read More
Press Release
Dispel Announces Industry's First Tiered Connection Suite for OT Secure Remote Access at the Gartner(R) Security & Risk Management Summit 2025
New capabilities deliver an end-to-end solution across all three remote access methods used in industrial operations-enabling a 93% reduction in standard connection times. Read More
Press Release
Ondas Secures $14.3 Million Order from a Leading Defense Customer for Optimus Drone Systems
Order Represents Largest Optimus System Order to Date, Reinforcing Expansion in Global Defense and Security Markets Increases Ondas' Backlog to $28.7 Million, Up from $10.0 Million at Start of 2025 Read More
Press Release
VIEWPOINT: Big Tech Just Saved Nuclear -Now It Needs Thermal Storage to Work
This is the second installment in Brenmiller Energy's "Viewpoint" Series, which explores the infrastructure, innovation, and storage technologies needed to build a resilient, low-carbon energy future. Read More
Press Release
Dedalus Named Europe's Top-Rated EHR for Workflow Alignment in Black Book Report Ahead of HIMSS25 Paris
Independent Global Study Evaluates EHR Satisfaction Across 110 Countries; 93% of European Users Say Dedalus Clinical Documentation Tools Better Align with Local Workflows than U.S. Vendors Read More
Press Release
DEA's Marijuana Defiance Deepens: Rogue Bureaucrats Undermine DOJ, Supreme Court, and Rule of Law
Terrance Cole's First Test: Will He Restore DEA Diversion To Legitimacy As the DEA Diversion spirals into constitutional crisis, all eyes now turn to incoming Administrator Terrance Cole. With the Supreme Court, DOJ, and Congress aligned on the illegality of the agency's ALJ system, Cole faces a clear mandate: dismantle the DEA's kangaroo court framework, remove corrupt leadership like Thomas Prevoznik, Matthew Strait and attorney Aarathi Haig, restore sound marijuana policy and return the agency to the rule of law. His next moves will determine whether the DEA Diversion can be salvaged-or whether it must be restructured from the ground up. Read More
Press Release
